


# **PRESS INFORMATION**



## **CytoTools AG takes over majority shareholding in its successful subsidiary DermaTools**


- Biotech enterprise now holds almost 52 %
- Biotech GmbH will use capital increase to further finance German DermaPro® clinical trials

Darmstadt, 2nd. May 2011 – Recently, the DermaTools Biotech GmbH shareholder's meeting decided unanimously to raise registered capital by 7.5 %. Within the scope of this capital increase, the CytoTools AG has now increased its participating share in the DermaTools Biotech GmbH to almost 52%. Now, more than 1 million EUR flow into DermaTools Biotech GmbH from the capital increase and other accompanying measures. The means will be used for the continuing clinical research into the DermaPro® active substance. Furthermore, by subscribing to the increase in capital, and therefore obtaining a majority shareholding, CytoTools is fulfilling the wishes of many shareholders and is strengthening its own position as the leading equity partner within DermaTools and the chief investor. For DermaTools Biotech GmbH, the capital raising measures means a comprehensive strengthening of liquidity. Furthermore, this successful financing step reflects the excellent course of the clinical development of DermaPro® in India and in Germany. In particular, this money guarantees the clinical developments of DermaPro® up to the market launch in India and the start of the Phase III study in Germany.

*This information contains certain forward-looking statements. These reflect the opinion of CytoTools at the date of this information release. The results which are actually achieved by CytoTools in the future may differ significantly from the statements made herein. CytoTools is not obliged to revise or update such forward-looking statements.*

**CytoTools AG**, previously CytoTools GmbH, is a technology and holding company which holds the following shares in its subsidiaries which carry out product development in the pharmaceutical and medical products field: 52% in DermaTools Biotech GmbH (therapy field dermatology, urology) and 46% in CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide by CytoTools AG and transferred to the subsidiary companies in the form of worldwide exclusive licenses.

# ***PRESS INFORMATION***



## ***PRESS INFORMATION***

### **Contact:**

CytoTools AG

Dr. Mark Andre Freyberg

Klappacher Str. 126

D-64285 Darmstadt

Tel.: +49-6151-95158-12

Fax: +49-6151-95158-13

E-Mail: [freyberg@cytotools.de](mailto:freyberg@cytotools.de)

### **Press contact:**

cometis AG

Alexandra Edinger

Unter den Eichen 7

D-65195 Wiesbaden

Tel.: +49-611-205855-16

Fax: +49-611-205855-66

E-Mail: [edinger@cometis.de](mailto:edinger@cometis.de)